These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 11837383)

  • 21. Influence of food on the pharmacokinetics of quinapril and its active diacid metabolite, CI-928.
    Ferry JJ; Horvath AM; Sedman AJ; Latts JR; Colburn WA
    J Clin Pharmacol; 1987; 27(5):397-9. PubMed ID: 3693584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and pharmacodynamics of benazepril in hypertensive patients with normal and impaired renal function.
    Shionoiri H; Ueda S; Minamisawa K; Minamisawa M; Takasaki I; Sugimoto K; Gotoh E; Ishii M
    J Cardiovasc Pharmacol; 1992 Sep; 20(3):348-57. PubMed ID: 1279278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Moexipril and quinapril inhibition of tissue angiotensin-converting enzyme activity in the rat: evidence for direct effects in heart, lung and kidney and stimulation of prostacyclin generation.
    Torsello A; Locatelli V; Cella SG; Sanguini AM; Berti F
    J Endocrinol Invest; 2003 Jan; 26(1):79-83. PubMed ID: 12602539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacokinetics and pharmacodynamics of quinapril and quinaprilat in renal impairment.
    Begg EJ; Robson RA; Bailey RR; Lynn KL; Frank GJ; Olson SC
    Br J Clin Pharmacol; 1990 Aug; 30(2):213-20. PubMed ID: 2144994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat in healthy cats.
    Desmoulins PO; Burgaud S; Horspool LJ
    J Vet Pharmacol Ther; 2008 Aug; 31(4):349-58. PubMed ID: 18638296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacokinetics and angiotensin converting enzyme inhibition dynamics of cilazapril in essential hypertension.
    Meredith PA; Elliott HL; Reid JL; Francis RJ
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):263S-266S. PubMed ID: 2548553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic and pharmacodynamic interaction trial after repeated oral doses of imidapril and digoxin in healthy volunteers.
    Harder S; Thürmann PA
    Br J Clin Pharmacol; 1997 May; 43(5):475-80. PubMed ID: 9159562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolism of moexipril to moexiprilat: determination of in vitro metabolism using HPLC-ES-MS.
    Kalász H; Petroianu G; Tekes K; Klebovich I; Ludányi K; Gulyás Z
    Med Chem; 2007 Jan; 3(1):101-6. PubMed ID: 17266629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moexipril. A review of its use in the management of essential hypertension.
    Brogden RN; Wiseman LR
    Drugs; 1998 Jun; 55(6):845-60. PubMed ID: 9617599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics.
    O'Grady P; Yee KF; Lins R; Mangold B
    Br J Clin Pharmacol; 1999 Sep; 48(3):375-81. PubMed ID: 10510149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults.
    Haroldsen PE; Musson DG; Hanson B; Quartel A; O'Neill CA
    Clin Ther; 2015 Jul; 37(7):1555-63. PubMed ID: 26101174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers.
    Bani M; Colantoni A; Guillaume M; Macchi F; Moroni G; Persiani S
    Br J Clin Pharmacol; 2000 Oct; 50(4):338-49. PubMed ID: 11012557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor.
    Moore KH; Cass LM; Dallow N; Hardman TC; Jones A; Boyce M; Prince WT
    Eur J Clin Pharmacol; 2001; 56(11):805-11. PubMed ID: 11294370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update.
    Song JC; White CM
    Clin Pharmacokinet; 2002; 41(3):207-24. PubMed ID: 11929321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to young and elderly patients with mild-to-moderate hypertension.
    Arner P; Wade A; Engfeldt P; Mouren M; Stepniewski JP; Sultan E; Bryce T; Lenfant B
    J Cardiovasc Pharmacol; 1994; 23 Suppl 4():S44-9. PubMed ID: 7527101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects.
    Chen JJ; Hewitt LA
    Drugs R D; 2018 Mar; 18(1):77-86. PubMed ID: 29392574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hemodynamic and humoral effects of parenteral therapy with intravenously administered ACE inhibitor quinaprilat in patients with advanced heart failure].
    Mitrovic V; Mudra H; Bonzel T; Schmidt W; Schlepper M
    Z Kardiol; 1996 Nov; 85(11):828-38. PubMed ID: 9064945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antihypertensive effects of moexipril, a new ACE inhibitor, as add-on therapy to nifedipine in patients with essential hypertension.
    Persson B; Widgren BR; Fox A; Stimpel M
    J Cardiovasc Pharmacol; 1995 Jul; 26(1):73-8. PubMed ID: 7564369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril.HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration.
    Kaiser G; Ackermann R; Brechbühler S; Dieterle W
    Biopharm Drug Dispos; 1989; 10(4):365-76. PubMed ID: 2758102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.